This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
David Feifel is a Professor Emeritus at UCSD Medical Center and a former Director of the Neurospsychiatry and Behavioral Medicine Program at the Center.
He is currently, Director of Kadima Neuropsychiatry Institute in La Jolla, California
Professor Feifel has a Diplomate American Board of Psychiatry and Neurology Certification in Neuropsychiatry and Behavioral Psychiatry Certification in Psychosomatic Medicine.